Benzylpiperazine: the New Zealand legal perspective.

BASSINDALE, Thomas (2011). Benzylpiperazine: the New Zealand legal perspective. Drug Testing and Analysis, 3 (7-8), 428-429.

Full text not available from this repository.
Link to published version:: https://doi.org/10.1002/dta.314
Related URLs:

    Abstract

    In 2005 the New Zealand Government created a new schedule of ‘Restricted Substances’ under the Misuse of Drugs Act (1975). Benzylpiperazine was the first drug to be classified as what became known informally as ‘Class D’. The rationale behind that decision and the subsequent reclassification of benzylpiperazine to Class C, in 2008, is discussed.

    Item Type: Article
    Research Institute, Centre or Group - Does NOT include content added after October 2018: Biomolecular Sciences Research Centre
    Identification Number: https://doi.org/10.1002/dta.314
    Page Range: 428-429
    Depositing User: Rebecca Jones
    Date Deposited: 08 Feb 2012 17:01
    Last Modified: 13 Jun 2017 12:52
    URI: http://shura.shu.ac.uk/id/eprint/4495

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year

    View more statistics